We are live on ! Find out more
VTVT icon

vTv Therapeutics

24 hedge funds and large institutions have $2.88M invested in vTv Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more capital invested

Capital invested by funds: $2.47M → $2.88M (+$412K)

0.01% less ownership

Funds ownership: 0.11%0.11% (-0.01%)

20% less funds holding

Funds holding: 3024 (-6)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

Holders
24
Holders Change
-6
Holders Change %
-20%
% of All Funds
0.38%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
4
Reduced
5
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
DT
26
Diversified Trust
Tennessee
-$12K -466 Closed
HF
27
HRT Financial
New York
-$10K -420 Closed
Prudential Financial
28
Prudential Financial
New Jersey
-$6.79K -260 Closed
Bank of America
29
Bank of America
North Carolina
-$46 -2 Closed
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
+$305 +9 +300%

VTVT Hedge Fund Activity: Q1 2023 in Review

24 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2023, worth a combined $2.88M — up 17% from $2.47M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of VTVT and 2 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 4 added.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $13K. The largest seller was HBK Sorce Advisory, exiting entirely with an estimated $38K sold.

  • 24 institutional investors held vTv Therapeutics (VTVT) as of Q1 2023, down from 30 in Q4 2022.
  • Funds reported $2.88M of vTv Therapeutics stock for Q1 2023, up 17% quarter-over-quarter.
  • 2 funds opened new vTv Therapeutics positions in Q1 2023 and 6 closed out, a net change of -4 holders.
  • The largest vTv Therapeutics buyer in Q1 2023 was Susquehanna International Group, an estimated $13K added.
  • The largest vTv Therapeutics seller in Q1 2023 was HBK Sorce Advisory, an estimated $38K sold.

Based on aggregated 13F filings for Q1 2023.